Issue 2/2013
Content (32 Articles)
The anti-cancer activities of jasmonates
Ziv Raviv, Sharon Cohen, Dortit Reischer-Pelech
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer
Siddharth Chachad, Shrinivas Purandare, Geena Malhotra, Raghu Naidu
Effect of topical chamomile on immunohistochemical levels of IL-1β and TNF-α in 5-fluorouracil-induced oral mucositis in hamsters
Marina Curra, Marco Antonio T. Martins, Isabel S. Lauxen, Ana Carolina A. Pellicioli, Manoel Sant’Ana Filho, Vanessa Christina S. Pavesi, Vinicius C. Carrard, Manoela D. Martins
CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients
Andreas Trojan, Athanasios Vergopoulos, Urs Breitenstein, Christoph Tausch, Burkhardt Seifert, Wolfgang Joechle
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
D. Ross Camidge, Normand Blais, Derek J. Jonker, Denis Soulières, Robert C. Doebele, Ana Ruiz-Garcia, Aron Thall, Ke Zhang, Scott A. Laurie, Richard C. Chao, Laura Q. Chow
A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer
M. Michael, J. Zalcberg, P. Gibbs, L. Lipton, M. Gouillou, M. Jefford, G. McArthur, M. Copeman, K. Lynch, N. C. Tebbutt
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts
Jianxia Guo, Dana M. Clausen, Jan H. Beumer, Robert A. Parise, Merrill J. Egorin, Karla Bravo-Altamirano, Peter Wipf, Elizabeth R. Sharlow, Qiming Jane Wang, Julie L. Eiseman
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer
Fumihiro Oshita, Makiko Sugiura, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada
Pharmacokinetic study and effectiveness evaluation of slow-release PLGA-5-fluorouracil microsphere
Jingquan Li, Yongdong Pu, Shiliang Wang, Manzhi Ding, Dianliang Chen, Mudan Zhu
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
F. Mueller, B. Büchel, D. Köberle, S. Schürch, B. Pfister, St. Krähenbühl, T. K. Froehlich, C. R. Largiader, M. Joerger
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
Cui Chen, Feng-hua Wang, Xin An, Hui-yan Luo, Zhi-qiang Wang, Ying Liang, Le Zhang, Yu-hong Li
In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation
Wei-Hua Hao, Jong-Jing Wang, Shu-Ping Hsueh, Pei-Jing Hsu, Li-Chien Chang, Chang-Shan Hsu, Kuang-Yang Hsu
Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
Apostolia M. Tsimberidou, Mark B. Leick, Joann Lim, Siqing Fu, Jennifer Wheler, Sarina A. Piha-Paul, David Hong, Gerald S. Falchook, Aung Naing, Ishwaria M. Subbiah, Adoneca Fortier, Rony Avritscher, Razelle Kurzrock
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma
Cormac Owens, Valerie Laurence, Lofti Benboubker, Anne-Sophie Defachelles, Didier Cupissol, Hervé Rubie, Hervé Brisse, Annie Rey, Liliane Ollivier, Dominique Couanet, Christiane Baunin, Céline Mahier Aït-Oukhatar, Odile Oberlin
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer
Sachi Morita, Keisuke Uehara, Goro Nakayama, Takashi Shibata, Tomoyo Oguri, Megumi Inada-Inoue, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Yuichi Ando
Combination of three cytotoxic agents in small-cell lung cancer
G. P. Stathopoulos, D. Trafalis, J. Dimitroulis, Ch. Kosmas, J. Stathopoulos, D. Tsavdaridis
Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection
Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naru Kondo, Naoya Nakagawa, Hayato Sasaki, Taijiro Sueda
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Wei-Xiang Qi, Feng Lin, Yuan-jue Sun, Li-Na Tang, Ai-Na He, Yang Yao, Zan Shen
Autophagy, cell death and sustained senescence arrest in B16/F10 melanoma cells and HCT-116 colon carcinoma cells in response to the novel microtubule poison, JG-03-14
Jonathan W. Biggers, Tuyen Nguyen, Xu Di, John T. Gupton, Scott C. Henderson, Sean M. Emery, Moureq Alotaibi, Kimber L. White Jr., Ronetta Brown, Jorge Almenara, David A. Gewirtz
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
Kazuhiro Kitamura, Kaoru Kubota, Masahiro Ando, Satoshi Takahashi, Nobuhiko Nishijima, Teppei Sugano, Masaru Toyokawa, Koji Miwa, Seiji Kosaihira, Rintaro Noro, Yuji Minegishi, Masahiro Seike, Akinobu Yoshimura, Akihiko Gemma
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar, Pietro Taverna, Aram Oganesian, Amarpal Sahai, Mohammad Azab, Anthony W. Tolcher
Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters
Tim A. D. Smith, M. Virginia C. L. Appleyard, Sheila Sharp, Ian N. Fleming, Karen Murray, Alastair M. Thompson
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
Sun Jin Sym, Junshik Hong, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Yeon Ho Park, Woon Ki Lee, Min Chung, Hyung-Sik Kim, Se Hoon Park, Dong Bok Shin
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
Matthew Hoffmann, Claudia Kasserra, Josephine Reyes, Peter Schafer, Jolanta Kosek, Lori Capone, Anastasia Parton, Heasook Kim-Kang, Sekhar Surapaneni, Gondi Kumar
Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice
Kosuke Okada, Dongmei Ma, Eiji Warabi, Naoki Morito, Kentaro Akiyama, Yasuhiro Murata, Kenji Yamagata, Hiroki Bukawa, Junichi Shoda, Tetsuro Ishii, Toru Yanagawa
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)
Soichiro Shibui, Yoshitaka Narita, Junki Mizusawa, Takaaki Beppu, Kuniaki Ogasawara, Yutaka Sawamura, Hiroyuki Kobayashi, Ryo Nishikawa, Kazuhiko Mishima, Yoshihiro Muragaki, Takashi Maruyama, Junichi Kuratsu, Hideo Nakamura, Masato Kochi, Yoshio Minamida, Toshiaki Yamaki, Toshihiro Kumabe, Teiji Tominaga, Takamasa Kayama, Kaori Sakurada, Motoo Nagane, Keiichi Kobayashi, Hirohiko Nakamura, Tamio Ito, Takahito Yazaki, Hikaru Sasaki, Katsuyuki Tanaka, Hideaki Takahashi, Akio Asai, Tomoki Todo, Toshihiko Wakabayashi, Jun Takahashi, Shingo Takano, Takamitsu Fujimaki, Minako Sumi, Yasuji Miyakita, Yoichi Nakazato, Akihiro Sato, Haruhiko Fukuda, Kazuhiro Nomura
A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez, Kyriakos Papadopoulos, Alejandro D. Ricart, E. Gabriella Chiorean, Robert S. DiPaola, Mark N. Stein, Caio M. Rocha Lima, James J. Schlesselman, Khaled Tolba, Virginia K. Langmuir, Stewart Kroll, Donald T. Jung, Metin Kurtoglu, Joseph Rosenblatt, Theodore J. Lampidis
Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
Peggy Gandia, Cécile Arellano, Thierry Lafont, Françoise Huguet, Laurence Malard, Etienne Chatelut
Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance
Consolación Melguizo, Jose Prados, Raquel Luque, Raúl Ortiz, Ana R. Rama, Octavio Caba, Fernando Rodríguez-Serrano, Pablo J. Álvarez, Antonia Aránega
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours
U. Lassen, W. H. Miller, S. Hotte, T. R. J. Evans, C. Kollmansberger, D. Adamson, D. L. Nielsen, J. Spicer, E. Chen, T. Meyer, K. Brown, R. Rafi, M. B. Sawyer
Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation
Yoon-Koo Kang, Byung Woog Kang, Seock-Ah Im, Jae-Lyun Lee, Sook Ryun Park, Won Ki Kang, Heung Moon Chang, Tae Won Kim, Do-Youn Oh, Kyung Hae Jung, Min-Hee Ryu
Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
Bojana Milojkovic Kerklaan, Veronique Diéras, Christophe Le Tourneau, Marja Mergui-Roelvink, Alwin D. R. Huitema, Hilde Rosing, Jos H. Beijnen, Sandrine Marreaud, Anne-Sophie Govaerts, Martine J. Piccart-Gebhart, Jan H. M. Schellens, Ahmad Awada